REACHAUT: First-line (1L) ribociclib (RIB) plus endocrine therapy (ET) in HR+, HER2-metastatic breast cancer (MBC) in the real-world setting.

Singer, CF; Oehler, L; Egle, D; Greil, R; Petru, E; Balic, M; Marhold, M; Pfeiler, G; Brunner, C; Kwasny, W; Galid, AA; Tinchon, C; Eisterer, W; Haslbauer, F; Hubalek, M; Redl, A; Hock, K; Hennebelle, M; Mraz, B; Steger, GG

View this publication in the PUBMED database